Dapsone success rate: what the acne trials actually show

Last updated 2026-07-30

What is the actual success rate of dapsone for acne?

The number most people are looking for comes from the FDA registration trials for topical dapsone gel 5% (brand name Aczone), published as part of the drug's approval package and later summarized in the dermatology literature. In the two 12-week, randomized, vehicle-controlled trials submitted to the FDA, investigators used a global acne assessment score and counted a patient as a treatment "success" if they were rated clear or almost clear at week 12 ^[1]. Across the two trials, roughly 41% to 48% of people using dapsone gel 5% hit that success mark, compared to about 30% to 33% of people using the vehicle gel (the same gel without the active drug) ^[1]. That gap, roughly 10 to 15 percentage points over placebo, is the real effect size. It's a solid but not dramatic result, in line with most topical acne drugs, not a cure. A separate 12-week study of dapsone gel 7.5% (the once-daily strength approved in 2016) found similar numbers: about 15.3% of patients using the drug reached zero or near-zero lesions by investigator global assessment versus about 11% on vehicle, with total lesion counts dropping by about 48.9% in the treatment group versus 43.2% for vehicle ^[2]. Different trial, different endpoint definition, similar story: real but modest improvement over placebo. None of this is a percentage chance of "curing" acne. It's a percentage of trial participants who reached a specific, pre-defined skin score after three months of daily use. Real-world results vary by skin type, acne severity, and how consistently someone actually applies it, which the trials can't fully capture. If you want a narrative sense of what results look like month to month, the dapsone results timeline breaks down what's realistic to expect and when.

How is topical dapsone different from oral dapsone, and why does the distinction matter for 'success rate'?

This is the single most important thing to understand before you go looking for a dapsone success rate, because the two forms are not the same drug in practice, even though they share an active ingredient. Topical dapsone (Aczone 5% and 7.5% gel) is FDA-approved specifically for acne vulgaris. It's applied to the skin, absorption into the bloodstream is minimal, and the FDA label states that G6PD deficiency testing is not required before starting it, because clinical trials didn't show clinically significant hemolytic effects even in G6PD-deficient patients using the topical form ^[2]. Oral dapsone is a sulfone antibiotic approved for dermatitis herpetiformis and leprosy (Hansen's disease), not for acne ^[3]. It works throughout the body, and it carries a real risk of dose-related hemolytic anemia, methemoglobinemia, and in rare cases a severe, delayed reaction called dapsone hypersensitivity syndrome that can include fever, rash, and organ involvement ^{[3] [4]}. Oral dapsone absolutely requires G6PD screening before starting, because patients with G6PD deficiency can develop severe, sometimes life-threatening hemolysis on standard oral doses ^{[3] [5]}. When you see "dapsone success rate" discussed online, almost all of the acne-specific data is about the topical gel. If a source is quoting acne clearance numbers next to warnings about hemolysis and blood counts, it's very likely blending the two drugs together, which is a serious conflation. Ask which formulation any given statistic is about before you act on it.

What percentage of people see improvement with topical dapsone gel?

Beyond the binary "success" endpoint, the trials also tracked percentage reduction in lesion counts, which gives a fuller picture of typical improvement. In the dapsone gel 5% trials, mean reductions in inflammatory lesion counts at week 12 ran higher in the treatment arms than vehicle arms, generally in the range of a 40% to 50% reduction in inflammatory lesions for dapsone versus somewhat lower reductions for vehicle, though exact figures differ slightly between the two published trials ^[1]. The 7.5% gel trial reported a 48.9% mean reduction in total lesions on active drug versus 43.2% on vehicle over 12 weeks ^[2], a smaller gap than the 5% data, which is part of why the 7.5% formulation's main selling point became once-daily dosing convenience rather than a bigger efficacy jump. Here's the honest read: most people using topical dapsone see meaningful but partial improvement, not total clearance, by 12 weeks. A meaningful minority see little difference from vehicle gel alone, which itself has some effect just from twice-daily gentle application and moisturizing. For a lesion-by-lesion sense of what "improvement" looks like in practice, dapsone before and after photos and patient descriptions fill in what the trial numbers can't.

How long does dapsone take to work for acne?

The FDA trials measured outcomes at 12 weeks, and that's the honest benchmark to plan around, not two weeks and not one week. Most prescribers and the trial data suggest looking for early signs (less new inflammation, calmer skin) around weeks 4 to 6, with the fuller effect showing up by weeks 8 to 12 ^{[1] [2]}. Acne treatments in general, including retinoids and benzoyl peroxide, follow a similar arc, because the skin cycle and inflammatory turnover simply take time. Judging dapsone gel at two weeks and calling it a failure is one of the most common reasons people quit a treatment that would have worked. There's also a well-known cosmetic side effect worth knowing up front: dapsone gel can cause a temporary orange-ish discoloration if used at the same time as benzoyl peroxide, though this is a surface staining issue, not a sign the drug isn't working or is unsafe ^[2]. Separating application times (one in the morning, one at night) usually avoids it. For a week-by-week expectation-setting guide, see dapsone first month what to expect.

Does dapsone work better for inflammatory acne or comedonal acne?

The trial data and the drug's mechanism both point the same direction: dapsone gel does more for inflammatory acne (papules and pustules) than for comedones (blackheads and whiteheads). Dapsone's anti-inflammatory and mild antimicrobial action targets the inflammatory side of acne, which is consistent with why the trials primarily tracked inflammatory lesion counts and global inflammatory assessment scores ^{[1] [2]}. It isn't a strong comedolytic in the way that topical retinoids (tretinoin, adapalene) are, and dermatology guidance from the American Academy of Dermatology generally positions topical dapsone as an option particularly useful for adult women with inflammatory acne, rather than as a first-line comedonal acne treatment ^[6]. This is why dapsone is frequently combined with a retinoid in practice: the retinoid handles comedones and turnover, dapsone handles inflammation. Used alone, someone with mostly blackhead-and-whitehead acne and little redness may not see the same benefit as someone with red, inflamed breakouts.

Is oral dapsone ever used for acne, and what are the risks?

Oral dapsone is not an FDA-approved acne treatment, and it isn't something a dermatologist reaches for as a routine acne option ^[3]. It's approved for dermatitis herpetiformis and leprosy, and off-label oral use in dermatology is generally reserved for severe, treatment-resistant inflammatory skin conditions, not standard acne, because the systemic risk profile is out of proportion to acne's severity as a disease. The core risk is dose-related hemolysis, meaning oral dapsone breaks down red blood cells to some degree in essentially everyone taking it, and that effect is dangerously amplified in people with G6PD deficiency, an inherited enzyme deficiency that affects an estimated 4.9% of the global population according to a widely cited genetic prevalence analysis ^[5]. The FDA label for oral dapsone specifically instructs clinicians to test G6PD status before starting therapy, and to monitor blood counts regularly during treatment ^[3]. Beyond hemolysis, oral dapsone carries risk of methemoglobinemia (reduced oxygen-carrying capacity of blood), agranulocytosis (dangerous drop in infectious-fighting white blood cells), and dapsone hypersensitivity syndrome, a rare but serious delayed reaction (typically appearing 3 to 6 weeks after starting) involving fever, rash, and potential liver or other organ involvement, with mortality estimates in published case reviews reaching approximately 9.9% among reported cases ^[4]. None of this is a reason to panic about the topical gel, which doesn't carry these systemic risks at meaningful levels ^[2], but it is a reason never to self-source oral dapsone for a cosmetic skin concern.

What is G6PD deficiency and why does it matter here?

G6PD (glucose-6-phosphate dehydrogenase) deficiency is a genetic condition, more common in people of African, Mediterranean, Middle Eastern, and Southeast Asian ancestry, that leaves red blood cells more vulnerable to oxidative stress ^[5]. Certain drugs, foods (notably fava beans), and infections can trigger a hemolytic episode in someone with this deficiency. Oral dapsone is one of the classic drugs that can trigger hemolysis in G6PD-deficient patients, which is why the FDA label calls for screening before treatment starts and periodic blood monitoring during it ^[3]. This is standard practice for any clinician prescribing oral dapsone for its approved uses (dermatitis herpetiformis, leprosy) or in the rare dermatology cases where it's used off-label for severe inflammatory skin disease. Topical dapsone gel is a different story. Systemic absorption through the skin is low enough that the FDA-reviewed trials, including ones that enrolled G6PD-deficient participants, did not show clinically significant hemolysis or the need for routine G6PD testing before starting the topical gel ^[2]. That's a genuinely reassuring distinction, and it's exactly the kind of detail that gets lost when success-rate statistics get generalized across both drug forms without specifying which one is meant.

How does dapsone's success rate compare to other topical acne treatments?

No head-to-head mega-trial puts dapsone gel directly against every other topical acne drug under identical conditions, so comparisons have to be made carefully, trial to trial, rather than as a clean ranking. | Treatment | Trial design | Reported success/improvement |

Does dapsone work for adult women with hormonal or jawline acne?

This is one of the more specific, well-supported use cases in the dapsone literature. Subgroup analyses of the trials found that adult women, especially those over 25 with predominantly inflammatory, lower-face and jawline acne, tend to respond well to topical dapsone gel ^{[1] [6]}. This fits the broader pattern of adult female acne, which tends to be more inflammatory and hormonally driven, clustered around the jaw and chin, and often more resistant to standard teenage-acne treatments. Dapsone's tolerability profile (less drying than benzoyl peroxide, safe alongside retinoids) makes it a common add-on in adult acne regimens even though it's not marketed specifically for this group. That said, subgroup data from a 12-week trial isn't the same as a study designed and powered specifically for adult hormonal acne, so treat this as a well-supported pattern rather than a guarantee.

Is dapsone worth trying if other acne treatments haven't worked?

Given a roughly 10 to 15 percentage point improvement over vehicle gel in the trials ^[1], topical dapsone is a reasonable next step for inflammatory acne that hasn't responded to benzoyl peroxide or a retinoid alone, particularly because it's well tolerated and safe to layer with those other treatments. It's not a rescue drug for severe cystic acne on its own, and it's not going to outperform isotretinoin for that population. Where it earns its place is as an add-on for inflammatory, moderate acne, especially in people who can't tolerate the dryness of stronger topicals. For a straight cost-versus-benefit read before you commit to three months of daily use, is dapsone worth it walks through price, insurance coverage patterns, and what a realistic ceiling of improvement looks like. And if you want to see what real users report rather than just trial statistics, dapsone reviews rounds up patterns across a wider range of experiences. If you and a provider decide topical dapsone makes sense for your skin, Dapsone Rx's provider-reviewed process connects you to a licensed prescriber, and prescriptions are filled through the pharmacy partner in the Dapsone Rx network rather than any compounding done in-house.

What side effects reduce the real-world success rate?

Trial success rates are measured under ideal conditions: consistent daily application, medical follow-up, no early dropout. Real-world adherence is messier, and side effects are the main reason people quit early, which quietly lowers real-world effectiveness compared to the trial numbers. The most commonly reported side effects of topical dapsone gel in trials were dryness, redness, and mild peeling at the application site, generally less severe than with benzoyl peroxide or tretinoin ^[2]. The orange-tinge interaction with benzoyl peroxide mentioned earlier is cosmetic, not dangerous, but it's a common reason people stop combination use or apply inconsistently. Oral dapsone's side effect profile is a different category entirely: nausea, headache, and in a meaningful subset of patients, the hemolysis and hypersensitivity risks already covered ^{[3] [4]}. That's a core reason oral dapsone isn't and shouldn't be treated as an acne option, no matter how the success-rate numbers get framed online.

Frequently asked questions

What is dapsone's success rate for acne in clinical trials?

In the FDA trials for dapsone gel 5%, about 41% to 48% of patients reached clear or almost clear skin at 12 weeks, versus about 30% to 33% on vehicle gel alone ^[1]. The 7.5% gel trial found about 15.3% reached a near-zero lesion score versus 11% on vehicle, with roughly 49% total lesion reduction ^[2].

Does dapsone gel actually clear acne or just reduce it?

For most users, dapsone gel reduces acne rather than fully clearing it. Trial data shows partial lesion reduction (roughly 40-50%) for most participants, with only a subset reaching "clear or almost clear" status by 12 weeks ^[1][2]. It's best understood as a meaningful improvement tool, not a cure.

Is oral dapsone used to treat acne?

No. Oral dapsone is FDA-approved for dermatitis herpetiformis and leprosy, not acne ^[4]. It's occasionally used off-label for severe inflammatory skin disease under specialist supervision, but its hemolysis and hypersensitivity risks make it inappropriate as a routine acne treatment.

Do I need a G6PD test before using dapsone?

For topical dapsone gel, no; FDA-reviewed trials didn't show clinically significant hemolysis even in G6PD-deficient participants using the gel ^[3]. For oral dapsone, yes; G6PD screening is required before starting because deficiency raises the risk of severe hemolysis on oral doses ^[4].

How long before I see results from dapsone gel?

Trial data is measured at 12 weeks, and that's the realistic benchmark. Some improvement may appear by weeks 4 to 6, but the full effect measured in FDA trials shows up closer to the 12-week mark ^[1][2]. Judging it earlier often leads people to quit before it's had a chance to work.

Why does my skin turn orange when using dapsone with benzoyl peroxide?

Combining dapsone gel with benzoyl peroxide can cause a temporary yellow-orange skin discoloration. It's a surface interaction between the two compounds, not a sign of harm or drug failure ^[3]. Applying them at different times of day (one AM, one PM) generally prevents it.

Is dapsone better than benzoyl peroxide or retinoids for acne?

No topical clearly outperforms the others across the board per AAD acne management guidance ^[7]. Dapsone tends to be gentler and better tolerated, with a modest inflammatory-lesion benefit, while retinoids handle comedones better and benzoyl peroxide has stronger antibacterial action. Many regimens combine dapsone with one of the other two.

Does dapsone work well for adult women's jawline acne?

Subgroup data from the trials suggests adult women with inflammatory, lower-face acne respond well to topical dapsone gel ^[1][7]. It's a common add-on in adult acne regimens for this reason, though it hasn't been studied in a trial designed specifically around that population.

What are the serious risks of oral dapsone?

Oral dapsone carries risk of dose-related hemolytic anemia (worse in G6PD deficiency), methemoglobinemia, agranulocytosis, and dapsone hypersensitivity syndrome, a rare delayed reaction with fever, rash, and organ involvement that carries a mortality rate estimated near 9.9% in case reviews ^[4][5]. These risks don't apply meaningfully to the topical gel.

What percentage of the population has G6PD deficiency?

Global genetic prevalence estimates put G6PD deficiency at roughly 4.9% of the population, with higher rates in people of African, Mediterranean, Middle Eastern, and Southeast Asian descent ^[6]. This matters primarily for oral dapsone, which requires screening before treatment starts.

Can dapsone gel cause the same hemolysis risk as oral dapsone?

Not at clinically meaningful levels. Topical dapsone's systemic absorption is low, and FDA-reviewed trials, including participants with G6PD deficiency, didn't find clinically significant hemolytic effects with the gel ^[3]. That's the key safety distinction between the two formulations.

Is topical dapsone gel FDA-approved for acne?

Yes. Dapsone gel 5% and the once-daily 7.5% formulation (Aczone) are both FDA-approved specifically for acne vulgaris, based on 12-week randomized, vehicle-controlled trials ^[1][2]. Oral dapsone does not share this acne approval.

Sources

1. FDA, Aczone (dapsone) gel 5% Prescribing Information / Clinical Studies section: Success rates of ~41-48% for dapsone gel 5% vs ~30-33% for vehicle at 12 weeks
2. FDA, Aczone (dapsone) gel 7.5% Prescribing Information: Dapsone gel 7.5% trial results: ~15.3% IGA success vs ~11% vehicle, 48.9% vs 43.2% lesion reduction
3. FDA, Dapsone Tablets USP Prescribing Information: Oral dapsone approved uses (dermatitis herpetiformis, leprosy), G6PD screening requirement, hemolysis and methemoglobinemia risk
4. Lorenz et al., 'Dapsone hypersensitivity syndrome' review, Journal of Clinical Pharmacy and Therapeutics / dermatology literature summary: Dapsone hypersensitivity syndrome mortality estimate near 9.9% in reviewed cases
5. Nkhoma et al., 'The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis', Blood Cells, Molecules, and Diseases (via NIH/PubMed): Global G6PD deficiency prevalence estimated around 4.9%
6. American Academy of Dermatology, Guidelines of care for the management of acne vulgaris: Comparative positioning of topical acne treatments including dapsone, adapalene, and benzoyl peroxide; adult female acne patterns